Sign in

Trial result ·

Efficacy and Safety of Crisugabalin for Inadequately Controlled Diabetic Peripheral Neuropathic Pain: A Randomized, Active-Controlled, Phase 2 Trial.

Written based on 1 research study on PubMed, searched on 5 Nov 2026.

What was studied

Crisugabalin is a GABA analog. It showed early signs of pain relief in diabetic peripheral neuropathic pain, or DPNP. It was unknown if it works in patients who responded poorly to pregabalin. This trial ran from April to July 2024. Adults got crisugabalin 40 mg a day or pregabalin 300 mg a day. Assignment was 1:1. Treatment lasted 4 weeks. The main goal was change in the SF-MPQ pain score.

What they found

47 patients got crisugabalin and 46 got pregabalin. The efficacy analysis included 90 patients. Their mean age was 58.9 years. Pain scores fell more with crisugabalin. The difference was -7.2 points, with p = 0.007. Adverse events occurred in 13 of 44 patients on crisugabalin. They occurred in 22 of 46 on pregabalin.

What it means for patients

The authors say crisugabalin gave greater pain reduction than pregabalin. The doses were 40 mg and 300 mg a day. This held over 4 weeks in patients who responded poorly to prior pregabalin.

Why it is not certain yet

The trial lasted 4 weeks. The abstract gives no longer-term results. A small trial can miss rare side effects.

Source

Efficacy and Safety of Crisugabalin for Inadequately Controlled Diabetic Peripheral Neuropathic Pain: A Randomized, Active-Controlled, Phase 2 Trial.

PubMed · PMID 42823911

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Type 2 diabetes publications